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Abstract
Objectives: The aim of this study was to demonstrate the existence of systematic associations in drug prescription
that lead to the establishment of patterns of polypharmacy, and the clinical interpretation of the associations found in
each pattern.
Methods: A cross-sectional study was conducted based on information obtained from electronic medical records and
the primary care pharmacy database in 2008. An exploratory factor analysis of drug dispensing information regarding
79,089 adult patients was performed to identify the patterns of polypharmacy. The analysis was stratified by age and
sex.
Results: Seven patterns of polypharmacy were identified, which may be classified depending on the type of disease
they are intended to treat: cardiovascular, depression-anxiety, acute respiratory infection (ARI), chronic obstructive
pulmonary disease (COPD), rhinitis-asthma, pain, and menopause. Some of these patterns revealed a clear clinical
consistency and included drugs that are prescribed together for the same clinical indication (i.e., ARI and COPD
patterns). Other patterns were more complex but also clinically consistent: in the cardiovascular pattern, drugs for the
treatment of known risk factors—such as hypertension or dyslipidemia—were combined with other medications for
the treatment of diabetes or established cardiovascular pathology (e.g., antiplatelet agents). Almost all of the patterns
included drugs for preventing or treating potential side effects of other drugs in the same pattern.
Conclusions: The present study demonstrated the existence of non-random associations in drug prescription,
resulting in patterns of polypharmacy that are sound from the pharmacological and clinical viewpoints and that exist
in a significant proportion of the population. This finding necessitates future longitudinal studies to confirm some of
the proposed causal associations. The information discovered would further the development and/or adaptation of
clinical patient guidelines to patients with multimorbidity who are taking multiple drugs.
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Introduction
Multimorbidity, which is defined as suffering from multiple
chronic diseases simultaneously, has begun to be considered a
major health problem affecting developed countries [1]. In
addition to its undesirable consequences for the patient (e.g.,
poorer quality of life and functional capacity) and health
services (e.g., misuse and saturation of services) [2],
multimorbidity presents a challenge for the physicians who are
responsible for the care of these patients because of the
absence of available evidence for the concurrent management
of multiple chronic diseases, among other factors. Despite
being effective for the individual diseases upon which they are
focused, most clinical practice guidelines (CPGs) do not pay
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enough attention to the presence of different health problems
within the same patient [3].
Drug therapy is an area in which this shortage of available
evidence is most clearly manifested since the use of multiple
disease-focused CPGs might lead to misinterpretations by
GPs. In fact, polypharmacy has frequently undesirable
consequences, such as increased risk of inappropriate drug
use, under-use of effective treatments, medication errors, poor
adherence, drug-drug and drug-disease interactions and, most
importantly, adverse drug reactions [4]. However, these threats
to the safety of patients, which may further compromise their
clinical situation, are rarely considered in the development of
CPGs [3]. This is of particular relevance in the Spanish
healthcare system, where a considerable proportion of
pharmaceutical prescriptions are induced by specialists [5,6],
who themselves are more subject to use a CPG for each
disease than GPs.
According to the European Forum for Primary Care, an
important step in producing and/or adapting the available
evidence to patients with multimorbidity lies in the
consideration of the systematic associations between diseases
and drugs [7]. In this regard, within the last five years, there
has been an increase in the number of studies aimed at
determining patterns of diseases (or multimorbidity) and their
underlying pathophysiological mechanisms. One of the most
recent studies, which was conducted in adults, revealed the
existence of five multimorbidity patterns that the authors name
as follows: 1) cardio-metabolic, 2) psychiatric-substance abuse,
3) mechanical-obesity-thyroid, 4) psychogeriatric, and 5)
depressive [8]. In addition to a warning about the urgent need
for a paradigm shift in the clinical approach to the patient, these
studies recommend investigating the existence of patterns of
polypharmacy (i.e., common associations between drugs) as
both causal and consequent factors of existing disease clusters
in the population.
The general objective of this paper is to show the existence
of systematic associations in drug prescription and use, which
create patterns of polypharmacy. The specific objectives are 1)
to describe drugs that constitute these patterns, 2) to estimate
the prevalence of these patterns, and 3) to interpret clinically
the associations found in each pattern.
Methods
A cross-sectional study was conducted based on data
obtained from electronic medical records and pharmacy billing
records for 79,089 patients who were over 14 years of age and
had been seen at least once by their family doctor in 2008. The
seven Zaragoza health centres that were included in the study
were previously selected based on criteria related to the quality
of the collected information [8].
Demographic variables of the age and sex were extracted
from patients’ electronic medical records. Data on prescribed
and dispensed active ingredients during 2008, and the date of
dispensing was obtained from the pharmacy billing records.
The active ingredients were coded according to the Anatomical
Therapeutic Chemical Classification System (ATC) [9],
considering the first three levels of the classification, to
facilitate the processing of the data. To ensure the concurrent
use of drugs for the same patient and to take account of drugs
with a seasonal utilisation, monthly dispensing frequencies for
each drug were first analysed, selecting the two months with
higher dispensing for the final analysis, namely, January and
February.
This study was favourably evaluated by the Clinical
Research Ethic Committee of Aragon (CEICA). Written consent
by patients was not needed since the study does not involve
interventions on individuals, the use of human biological
samples, or the analysis of personally identifiable data. Instead,
the present work is based on the statistical analysis of
anonymous data contained in previously existing databases
which were obtained with prior permission from the
corresponding entity.
Statistical Analysis
All of the analyses were stratified by sex and age; the latter
variable was grouped into three intervals: 15-44, 45-64, and
≥64. The identification of patterns of polypharmacy was based
on exploratory factor analysis, which is one of the methods
commonly used to identify patterns of multimorbidity [10]. The
strength of this technique is that, in addition to identifying non-
random associations between groups of variables, it allows a
single variable to be part of different patterns. Drugs with over
1% prevalence in each age and sex group were included in the
analysis to yield epidemiologically relevant results.
The factor analysis was based on a tetrachoric correlation
matrix, and the factor extraction was performed using the
principal factor method. The number of factors to extract was
determined using sedimentation graphs (Figure A in File S1)
and the clinical evaluation from the different solutions. The
adequacy of the sample was analysed using the Kaiser-Meyer-
Olkin (KMO) parameter, and the cumulative proportion of the
variance as a measure of model fit was obtained. To determine
the drugs that belonged to each pattern, those medications
with scores higher than 0.30 for each factor were selected
(Tables A-F in File S2). The clinical interpretation of the
patterns was conducted by three medical doctors (two
specialising in family medicine [LGF and FGR] and one
specialising in preventive medicine [APT]), one pharmacist
[MLS], and one epidemiologist [ACL].
To estimate the prevalence of the individual patterns of
polypharmacy, the number of individuals who had a certain
pattern was determined, considering that an individual
belonged to the pattern if he/she had been dispensed at least
three of the drugs included in the pattern. It is understood that
the threshold of three drugs dispensed simultaneously could
justify, by itself, some of the undesirable effects of
polypharmacy [11].
The STATA 11.0 software was used for the statistical
analyses.
Results and Discussion
The study population was composed of 79,089 patients who
were over 14 years of age (with a mean age of 47 years), of
which 55.03% were women (Table 1). In total, 63.8% of the
Polypharmacy Patterns
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men aged 15-44 years were taking no medication, a figure that
decreased to 9.75% for those men over 64 years of age. The
concurrent use of drugs increased with age in both men and
women; 70.91% of the men and 80.19% of the women over 64
years of age used more than two medications, and 36.65% and
47.6%, respectively, used over five medications (Table 1).


















































































































































































































































































Seven patterns of polypharmacy were identified in this study,
which, depending on the type of disease they are intended to
treat, may be classified as cardiovascular, depression-anxiety,
acute respiratory infection (ARI), chronic obstructive pulmonary
disease (COPD), rhinitis-asthma, pain, and menopause. The
first four patterns occurred in both men and women, the
following two occurred only in men, and the latter occurred only
in women (Table 2).
A clear clinical consistency was identified in some of these
patterns because they encompassed various therapeutic
groups with a common clinical indication—as was the case for
the ARI or COPD patterns. Other patterns were more complex
but also clinically consistent; this was the case of the
cardiovascular pattern, which included medications for the
treatment of known risk factors (i.e., diabetes, hypertension, or
dyslipidemia) along with other medications aimed at preventing
complications (e.g., antiplatelet agents). Finally, this study also
discovered associations that are difficult to explain based on
the available clinical knowledge and that should facilitate the
design of future research efforts.
The various identified patterns of polypharmacy are analysed
in detail below.
Cardiovascular pattern
The cardiovascular pattern is present in men and women
from age 45 years onwards (Table 3). Among middle-aged
women (i.e., 45-64 years), the pattern has a prevalence of 4%
and comprises antidiabetics, lipid-lowering drugs, diuretics,
angiotensin-converting enzyme (ACE) inhibitors, angiotensin II
receptor antagonists (ARBs), beta-blockers, calcium channel
blockers, antiplatelet agents, and antiglaucoma eye drops.
Except for the latter, the other drugs are indicated for the
treatment of cardiovascular risk factors (i.e., hypertension,
diabetes mellitus, and dyslipidemia) [12] and for the primary or
secondary prevention of clinically established arteriosclerosis
[13]. Among the reasons for the presence of antiglaucoma
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0.09 COPD 5.18 COPD 25.34
   Pain 4.52   
* Numerator: individuals with three or more drugs of the pattern within each age
and sex group; Denominator: the entire population within each age and sex group.
doi: 10.1371/journal.pone.0084967.t002
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medications in this pattern, it may be noted that both
hypertension [14] and diabetes [15] are risk factors for
glaucoma and that glaucoma may be caused by one of the
drugs included in the pattern (i.e., diuretics) [16]. In the latter
case, this would be an example of treatment of a side effect
that is not included in the main CPGs for cardiovascular
disease.
After 65 years of age, the prevalence of this pattern
increases in women, being present in almost one out of ten. In
addition, new drugs are added as possible treatments for some
of the complications in these patients, such as nitrites for
ischaemic heart disease, digoxin and aldosterone inhibitors for
heart failure, and hypouricemic drugs, which are frequently
prescribed for cardiovascular disease [17] as a possible
treatment of the side-effects of diuretics. It is noteworthy that, in
this age group, there are no ARBs, lipid-lowering drugs or
antiglaucoma medications that are used. The use of ARBs both
as monotherapy [18] or in combination with (ACE) inhibitors
[19] has been questioned in last years. Regarding lipid-
lowering drugs, a recent meta-analysis revealed no reduction in
the overall mortality of women treated with statins for
secondary prevention [20]. As for antiglaucoma medication, no
explanation could be found for its disappearance from the
cardiovascular pattern. Finally, the absence of proton pump
inhibitors (PPIs) in this pattern is striking; the use of these
drugs as gastroprotectants is widely recommended for patients
taking antiplatelet agents [21].
In men who are 45 to 64 years of age, the pattern almost
triples in prevalence compared with women (11%) and is very
similar in terms of its composition. This greater prevalence of
the pattern is consistent with the increased frequency of
cardiovascular disease in men. Other relevant differences with
regard to women are as follows: nitrites are used in ischaemic
heart disease, which occurs earlier in men; hypouricemic drugs
begin to be used; and PPIs appear, which could be associated
with the use of antiplatelet agents in patients for whom these
drugs are indicated in the CPGs [21].
During old age, after 65 years, the prevalence of this pattern
of polypharmacy increases until it is present in one out of four
men. Regarding the therapeutic groups that comprise this
pattern, there are three important differences compared with
women of the same age: 1) the sustained use of PPIs, 2) the
absence of drugs for heart failure, and 3) the additional use of
lipid-lowering drugs. The latter difference may be due to an
increased cardiovascular risk in men and their increased
incidence of ischaemic heart disease and cerebrovascular
disease—with the effectiveness of lipid-lowering drugs being
less evident in women [20]. It is not possible to rule out the
possible underdiagnosis and undertreatment of this disease in
women, as has been previously described [22].
In summary, this study allowed for the identification of a
clinically consistent cardiovascular pattern of polypharmacy
that exhibits a clear relation to the recently described cardio-
metabolic multimorbidity pattern (2) and that develops
differently based on the gender and age. The present
investigation also revealed the presence of unexpected
associations (i.e., antiglaucoma drugs in middle-aged women)
or the absence of certain drugs (such as PPIs) in older women,
which opens new and relevant research areas.
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Depression-anxiety pattern
This is a highly prevalent pattern, present in all age and
gender groups, with a wide range of variation in their
composition and frequency of occurrence (i.e., at advanced
ages, the frequency ranges between 37% in women and 0.3%
in men) (Table 4). The lower prevalence of this pattern in men
is striking, a difference that would presumably diminish if
certain drugs that had values slightly below the established cut-
off were considered (e.g., anxiolytics with a factor score of
0.23). The group of drugs that comprise this pattern (i.e.,
antidepressants, antipsychotics, anxiolytics, and sedatives) are
used in clinical practice for the treatment of anxiety disorders,
depression, and neurosis. The presence of antiepileptic drugs
such as gabapentin, both in men and women under 65 years of
age, is remarkable. This drug might be used off-label as a
modulator of behaviour disorders in psychotic patients [23,24];
the drug might also be administered as an adjuvant medication
for pain uncontrollable with regular analgesia.
Despite the clinical coherence in most of the associations
between drugs, other associations were detected, for which it
has not been possible to find a causal explanation. This is the
case of antiandrogens (i.e., ethinyloestradiol and cyproterone)
in young women aged 15 to 44 years, although future studies
should continue to shed light on the possible association
between acne beginning at puberty and depression [25].
In young men aged 15 to 44 years, lipid-lowering
medications and drugs for peptic ulcer and gastro-oesophageal
reflux are added to the pattern. The presence of the latter
medications could be justified because of the association
between antidepressants and upper gastrointestinal tract
bleeding [26] or gastro-oesophageal reflux disease [27].
However, it might be asked why gastroprotectants are not part
of this pattern in women of this age group, which is certainly a
question for future research.
Among patients aged 45 to 64 years, opioids are added to
this pattern, which may be explained by the association for
depression-somatisation pain [28,29]. In women, anti-
inflammatory drugs, antirheumatic drugs, and centrally acting
muscle relaxants are also included. The presence of
gastroprotectants (i.e., gastroprokinetic agents, laxatives, and
drugs for peptic ulcer and gastroesophageal reflux) could be
due to the treatment of side effects of antidepressants.
After 65 years of age, this pattern of polypharmacy
corresponds to a clinical situation of serious mental illness and
it includes antidepressants, anxiolytics, and anticonvulsants in
women as well as antidepressants, antipsychotics, and
dopaminergic agents in men. Furthermore, in women, an
analgesic component appears in this pattern, which consists of
the same drug groups as that for middle-aged women (e.g.,
opioids) and topical preparations for joint pain. The use of
laxatives and gastroprokinetic agents is present in both sexes,
most likely in response to the adverse effects of opioids [30]. In
women, this pattern may reflect the treatment of fibromyalgia
syndrome [31], although they are also administered calcium,
iron, and vitamin B12 as possible preventive treatments or in
the case of overt deficits.
In men over 65 years of age, it is possible to hypothesise
that this pattern relates to the treatment of psychogeriatric
diseases, comprising dopaminergic agents prescribed for
parkinsonism, in addition to the previously mentioned drugs
[32]. In the latter group, no acceptable explanations have been
Table 4. Depression-anxiety pattern composition according
to age and sex.
 15-44 years 45-64 years ≥65 years
Women Antiandrogens Antacids Antidepressants
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doi: 10.1371/journal.pone.0084967.t004
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found for the presence of cardiac glycosides, capillary agents
(i.e., diosmin and oxerutins), and/or topical antihaemorrhoidal
agents.
In conclusion, some of the findings within this complex
pattern indicate associations between drugs that are difficult to
explain from the available clinical knowledge. It has also been
impossible to elucidate the causes of certain differences
observed between the sexes, such as the absence of
antipsychotics in older women or the absence of vitamin B12
and folic acid in older men.
Acute respiratory infection (ARI) pattern
This pattern is present in men from 15 to 44 years of age and
in women up to 64 years (Table 5). In women aged 15 to 44
years, the prevalence of the ARI pattern is high (8%) and
comprises many medications related to the treatment of ARI
and its complications (i.e., residual cough or bronchospasm).
We found two associations that could be related to treatment
with other drugs: PPIs, which are gastroprotectants used in
patients treated with NSAIDs, and antifungal drugs for the
treatment of candidiasis secondary to antibiotics. Moreover,
this pattern includes two groups of drugs for which we found no
clinically reasonable explanation: topical corticosteroids and
anxiolytics.
In middle-aged women, the prevalence of this pattern is very
similar to that in young women (7%), but with interesting
therapeutic absences: 1) NSAIDs, perhaps due to
underprescribing because of the risk of digestive and
cardiovascular side effects (consequently, PPIs also do not
appear); 2) antifungals for topical use, most likely due to the
lower incidence of vaginal candidiasis in postmenopausal
women [33]; and 3) the two treatment groups of difficult clinical
explanation found among younger women (i.e., topical
corticosteroids and anxiolytics). Furthermore, the association of
systemic corticosteroids, due to the worsening of COPD, is
noteworthy [34].
Between 15 and 44 years of age, the prevalence of this
pattern in men is one-half that in women of the same age (4%)
and comprises analgesics, NSAIDs with their associated PPIs,
antibiotics, and drugs for the symptomatic treatment of cough.
With respect to women of the same age, opioids,
sympathomimetic bronchodilators, nasal decongestants, and
the previously discussed therapeutic groups of difficult clinical
explanation disappear.
In summary, the ARI pattern is highly prevalent—probably
due to the use of pharmacy data from the months of January
and February—and comprises a group of drugs administered
for the same category of diseases, including medications (e.g.,
vaginal antifungal agents and PPIs) that are used to treat
complications of these illnesses or the side effects of other
drugs. Some of the associations that have been found,
especially in young women, should be further investigated.
COPD pattern
The COPD pattern appears in men over 44 years of age, and
it is delayed in women until the age of 65 years (Table 6). This
pattern includes drugs for the treatment of airway obstruction
(i.e., systemic corticosteroids, expectorants, and
antihistamines) along with other medications for the treatment
of symptoms (e.g., analgesics, antitussives, and antipyretics).
The presence of antihistamines and antitussives indicates the
differential diagnosis between COPD and other allergic and/or
asthmatic processes, in which the presence of cough and
wheezing is common. As a pattern of polypharmacy that
corresponds to a chronic and advanced disease, the fact that
this pattern appears in a more delayed form in women may
Table 5. ARI pattern composition by age and sex.
 15-44 years 45-64 years
≥65
years
Women Adrenergics, inhalants Adrenergics, inhalants  
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doi: 10.1371/journal.pone.0084967.t005
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reflect a lower prevalence and intensity of smoking in women
[35].
In men over 64 years of age, this pattern is present in one
out of four individuals and comprises the same drugs that are
used by middle-aged individuals, to which NSAIDs and drugs
for peptic ulcer and gastro-oesophageal reflux are added. The
presence of calcium in this pattern is possibly due to its use for
the prevention of osteoporosis in patients taking
corticosteroids. Opioids also appear, prescribed probably as
antitussives or analgesics in patients with COPD [36].
In older women, this pattern has a prevalence of 7% and
exhibits certain peculiarities, namely, the absence of opioids,
eye lubricants, and calcium. It is necessary to consider what
the possible causes are. Finally, it should be mentioned that
PPIs, which are prescribed for protection against NSAIDs or
the gastric reflux induced by beta-2 mimetics, do not appear to
be associated to this pattern among women.
Rhinitis-asthma pattern
The rhinitis-asthma pattern occurs with a low frequency and
exclusively in young men (0.1%), and it is highly consistent
from the clinical viewpoint (Table 7). This pattern comprises
three therapeutic groups used for two pathologies with a
common aetiology: nasal corticosteroids and systemic
antihistamines for the treatment of allergic rhinitis [37] and
inhaled beta-adrenergic agonists for the treatment of asthma
[38].
Pain pattern
The pain pattern appears only in men who are 45 to 64 years
of age, affecting 5% of the patients in this group (Table 8). This
pattern includes analgesic drugs (e.g., acetaminophen, and
opioids), NSAIDs, central muscle relaxants, and other
medications for the treatment of side effects (i.e., drugs for
peptic ulcer). The presence of low-ceiling diuretics (e.g.,
chlorthalidone and indapamide) that are used in clinical
practice for mild essential hypertension is prominent [39]. It is
possible that these drugs are prescribed to combat the
hypertensive effect of NSAIDs. This finding would be clinically
relevant if the physician were addressing the potential
gastrolesivity of NSAIDs but not the possible vascular-renal
damage. If future longitudinal studies confirm this finding, then
specific indications in the CPGs should be designed to
recommend against the prescription of NSAIDs as long-term
analgesics.
Menopause pattern
The menopause pattern has a low prevalence—1% of
women aged 45-64 years-(Table 9) and includes two groups of
drugs: the first group, consisting of oestrogen,
bisphosphonates, and calcium for the prevention or treatment
of the effects of menopause (i.e., hot flashes and
osteoporosis), and the second group, consisting of drugs
prescribed for the symptomatic relief of some of the side-
effects described in the literature (e.g., ocular inflammation
caused by bisphosphonates) [40]. Despite its low prevalence,
the existence of this pattern is striking, to the extent that
Table 6. COPD pattern composition by age and sex.
 
15-44
years 45-64 years ≥65 years
Women   Adrenergics, inhalants
   Antihistamines for systemic use
   Antiinfectives
   Antiinfectives for systemic use
   Antiinfectives for systemic use
   
Antiinflammatory agents and
antiinfectives in combination
   
Corticosteroids for systemic use,
plain
   
Cough suppressants, excluding
combinations with expectorants
   
Decongestants and other nasal
preparations for topical use




   
Other drugs for obstructive airway
diseases, inhalants






































Corticosteroids for systemic use,
plain
   
Cough suppressants, excluding
combinations with expectorants
   
Drugs for peptic ulcer and gastro-
oesophageal reflux disease




   Opioids
   
Other drugs for obstructive airway
diseases, inhalants
   Other analgesics and antipyretics
   Other ophthalmologicals
doi: 10.1371/journal.pone.0084967.t006
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various studies have demonstrated that both oestrogen and
bisphosphonates have potentially serious side effects [41].
Strengths and limitations
The main strengths of the present study are the large
population size and the quality of the data in the pharmacy
database (i.e., pharmacy billing records), which yield greater
reliability and representativeness compared with other studies
that are based on medical records or surveys of drug use [42].
The exploratory factor analysis that was employed in this
study, in addition to being the technique that best responds to
Table 7. Rhinitis-asthma pattern composition according to
age and sex.
 15-44 years 45-64 years    ≥65 years
Women    
Men Adrenergics, inhalants   
 Antihistamines for systemic use   
 




Table 8. Pain pattern composition according to age and
sex.
 15-44 years   45-64 years ≥65 years
Women    
Men  








Drugs for peptic ulcer and gastro-
oesophageal reflux disease
 
  Low-ceiling diuretics, excluding thiazides  
  Muscle relaxants, centrally acting agents  
  Opioids  
  Other analgesics and antipyretics  
  Topical products for joint and muscular pain  
doi: 10.1371/journal.pone.0084967.t008
Table 9. Menopause pattern composition according to age
and sex.
 15-44 years    45-64 years ≥65 years
Women  Calcium  
  Decongestants and antiallergics  
  
Drugs affecting bone structure and
mineralisation
 
  Oestrogens  
  Other ophthalmologicals  
Men    
doi: 10.1371/journal.pone.0084967.t009
the proposed objective, was performed according to the
recommendations of Costello et al. [43]. Moreover, the
goodness-of-fit values of the models expressed as the
cumulative percentage of variance (i.e., between 19.47% and
58.54%) and the sampling adequacy (i.e., a KMO parameter
between 0.66 and 0.73) are above the acceptable limits.
Although several hypotheses have been presented regarding
the pathophysiological processes that underlie the seven
polypharmacy patterns revealed in this study, the former must
be interpreted with the necessary caution since the study
design (i.e., transversal) does not allow for the establishment of
the sequence in which medications cluster within a pattern.
Longitudinal studies would be necessary to corroborate the
suggested causal associations and to elucidate those
associations that could not be explained in the present study.
Another limitation of this study stems from the lack of
information on the actual use of drugs by the patients because
the pharmacy database contains information on the drugs that
are prescribed and dispensed at the pharmacy, without
providing proof of their consumption. Yet, this is currently the
data source of choice when carrying out population-based
studies on drug use, as stated previously.
Access to data on the use of over-the-counter (OTC)
medications was not available, which could lead to an
underestimation of the actual drug utilisation. Additionally, only
patients seen by their GP in 2008 were included in the study.
By doing so, prevalence figures of polypharmacy patterns may
overestimate the real frequency in the studied age and sex
groups. However, we believe this drawback may not have
interfered with the essential objective of the study, that is, to
analyse systematic associations in drug prescription and use.
Because these data were obtained from seven different
health centres, there may be differences in the socioeconomic
status and/or accessibility to public health care among
members of the target population; however, this heterogeneity
across individuals would increase the external validity of the
results. Some variability might also exist between the centres in
the drug prescription practices of their health professionals,
which would directly influence the results. Similarly, potential
differences in the organisational or functional aspects of each
centre (e.g., organisation of the pharmacy or laboratory) could
indirectly influence the associations obtained. Therefore, the
fact that the therapeutic group variable has been analysed with
the information obtained up to the third level of the ATC
classification (i.e., by the therapeutic family rather than by the
active ingredient) would reduce the possible variability between
the centres and professionals in determining the patterns of
polypharmacy.
No distinction was made regarding the level of care where
prescriptions originated albeit the importance of induced
prescription in primary care, as stated in the introduction.
Future studies should consider this information in order to
elucidate the impact of the primary-secondary care interface on
the nature and intensity of polypharmacy.
Comparisons with other studies
Comparing our results with those of other studies is difficult,
mainly because of the lack of similar studies in the scientific
Polypharmacy Patterns
PLOS ONE | www.plosone.org 8 December 2013 | Volume 8 | Issue 12 | e84967
literature. In fact, the present study is the first investigation of
the patterns of polypharmacy to be conducted in the general
population. Research in the field of pharmacoepidemiology
remains driven by the hermetic single-disease-single-
medication framework required in clinical trials [44]. However,
in no cases have combinations of medications been broadly
analysed at a population level to determine the specific
interactions and synergistic effects between them. Several
studies have examined the co-prescription of drugs, but only
for index-specific diseases. For example, Hoffmann et al. [45]
described comorbidity and polypharmacy in patients with
dementia, as did Franssen et al. [46] for patients with COPD.
Conclusions
This study revealed systematic associations in drug
prescription that affect a significant proportion of the population
and that are present in all of the age and sex groups that were
studied. These associations yield patterns of polypharmacy
that are consistent from the pharmacological and clinical points
of view. Seven patterns of polypharmacy were identified:
cardiovascular, depression-anxiety, acute respiratory infection
(ARI), chronic obstructive pulmonary disease (COPD), rhinitis-
asthma, pain, and menopause.
The clinical interpretation of the relations between the drugs
that give rise to these patterns allows us to hypothesise the
existence of underlying causal factors that are often related,
not to the disease itself, but to the adverse effects of the
prescribed treatments, which would explain many of the
observed associations.
The present study highlights the necessity of developing
future longitudinal studies, including the joint analysis of
diseases and drugs, which would facilitate the validation of
certain potential interactions described in this article. This
information would be an essential source for the development
of CPGs addressing multimorbidity and the design of clinical
management strategies and models of care with the capacity to
respond appropriately to the real health needs of patients with
multiple chronic conditions.
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